Nurix Therapeutics Inc
For the period ended Feb 29, 2024. Filed Apr 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Feb 29, 2024 · Filed Apr 10, 2024
NRIX$15.88-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
(in thousands)
| Three Months Ended | ||
|---|---|---|
| February 29, 2024 | February 28, 2023 | |
| Net loss | $(41,518) | $(40,733) |
| Other comprehensive income (loss), net of tax: | ||
| Unrealized gain (loss) on available-for-sale marketable securities | 305 | 1,072 |
| Total comprehensive loss | $(41,213) | $(39,661) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.